With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.5308-25-8,1-Ethylpiperazine,as a common compound, the synthetic route is as follows.
5308-25-8, 4.00 g (19.7 mmol) of 5-bromo-2-nitropyridine, 3.40 g (2.98 mmol) of 1-ethylpiperazine, 4.10 g (29.6 mmol) of potassium carbonate, 0.4 g (1.2 mmol) of tetrabutylammonium iodide, and 40mL of DMSO were added to a reaction flask, and reacted at 80C for 16 h. The reaction solution was then poured into ice-water and extracted three times with dichloromethane (20 ml for each time). The organic phases were combined, dried with anhydrous sodium sulfate, filtered, concentrated and separated by column chromatography (DCM/MeOH = 100:1-10:1) to give 3.59 g of yellow solid, yield 56.1%. MS (ESI): m/z 237.2 [M+H]+.
The synthetic route of 5308-25-8 has been constantly updated, and we look forward to future research findings.
Reference£º
Patent; Gan & Lee Pharmaceuticals; YIN, Lei; LIU, Wenjian; LI, Heng; ZHU, Dianxi; (73 pag.)EP3385262; (2018); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics